Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU
admission and mortality rate of critically ill patients with severe COVID-19 pneumonia …

There seem to currently be no therapeutic medications found for the severe coronavirus
infection in 2019 (COVID-19). In light of this, it has been hypothesized that the …

Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …

Introduction The aim of this study was to determine the efficacy of early tocilizumab treatment
for hospitalized patients with COVID-19 disease. Methods Open-label randomized phase II …

Background Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced
cytokine release syndrome and it may provide clinical benefit for selected COVID–19 …

Limited evidence is available to guide treatment of coronavirus disease 2019 (COVID-19),
caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A …

Abstract Coronavirus disease 2019 (COVID‐19) due to infection with severe acute
respiratory syndrome coronavirus 2 causes substantial morbidity. Tocilizumab, an …

Abstract Background Coronavirus disease 2019 (COVID-19) has killed over 2.5 million
people worldwide, but effective care and therapy have yet to be discovered. We conducted …

Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …

Background Data on the safety and efficacy profile of tocilizumab in patients with severe
COVID-19 needs to be enriched. Methods In this open label, prospective study, we …